Flow-cytometric analysis suggested that tumor progression (from days 11 to 25) results in increased frequencies of CD45+CD11chighCD11b−MHCIIhigh lymphoid-DC, with the majority of DCs exhibiting a CD8α+ phenotype and expressed a significant amount of cd3ε (Figures 4B,C1,C2). This evidence concerns the gene PTPRC and neoplasm.